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Abstract
Microglia are dynamic immune cells with diverse roles in maintaining homeostasis of the central nervous system.
Dysregulation of microglia has been critically implicated in the genesis of neuropathic pain. Peripheral nerve injury,
a common cause of neuropathic pain, engages microglia-neuronal signalling which causes disinhibition and
facilitated excitation of spinal nociceptive pathways. However, recent literature indicates that the role of microglia in
neuropathic pain is sexually dimorphic, and that female pain processing appears to be independent of microglia,
depending rather on T cells. Despite this sex difference, pain signalling in the spinal cord converges downstream of
microglia, as NMDAR-mediated facilitated excitation in pain transmitting neurons is consistent between males and
females. Determining whether pain signalling is sexually dimorphic in humans and, further, addressing the sex bias
in pain research will increase the translational relevance of preclinical findings and advance our understanding of
chronic pain in women.
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Introduction
Chronic pain is a highly prevalent and economically costly
health condition [1, 2]. In the United States, at least 116
million adults have chronic pain with an estimated annual
cost of $560-$635 billion [1]. Neuropathic pain, a com-
mon form of chronic pain, is caused by a lesion to or dis-
ease in the peripheral or central somatosensory nervous
system [3]. Neuropathic pain is characterized by spontan-
eous pain, hyperalgesia and allodynia (pain hypersensitiv-
ity) [4]. Spontaneous pain is persistent or paroxysmal pain
that is not elicited by a stimulus. Hyperalgesia is increased
pain response to a noxious stimulus while allodynia (pain
hypersensitivity) is pain in response to a normally innocu-
ous stimulus.
Preclinical studies using rodent models of neuropathic
pain have implicated spinal microglia as key mediators of
peripheral nerve injury (PNI)-induced pain hypersensitivity
[5–7]. However, evidence suggests that the role of microglia
in neuropathic pain is sex-dependent [8]. This sexual di-
morphism was only recently discovered as preclinical pain
research has generally excluded female subjects. The con-
sensus was that oestrus caused increased variability, now
shown not to be the case [9, 10]. Consequently, the over-
whelming majority of preclinical pain research is conducted
using only male rodents [11], a sex bias reflective of the bio-
medical field as a whole [12]. This sex bias poses serious
issues for the translational relevance of preclinical pain re-
search given that women represent the majority of patients
with chronic pain, including neuropathic pain [2, 13, 14].
Additionally, women appear to be more sensitive to experi-
mentally induced pain [15, 16]. Sex differences in response
to pain treatment in humans have also been reported [16],
such as increased morphine analgesia in females [17].
Microglia ontogeny and function
Microglia constitute an estimated 10% of centrally located
cells and are the principal immune cell of the central ner-
vous system (CNS) [18, 19]. As such, microglia maintain
physiological homeostasis by responding directly to insults
to CNS integrity such as traumatic brain injury, toxins,
pathogens or other physiological stressors. Threats to the
CNS produce characteristic microglial responses including
proliferation, changes in morphology, antigen presentation
and release of pro-inflammatory signalling molecules such
as cytokines [19, 20]. Microglia share functional similarities
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to macrophages, which are innate immune cells involved in
peripheral inflammation, but are distinct in cellular origin
[21]. Microglia derive from primitive myeloid progenitors
which originate in the yoke sac prior to embryonic day 8
and populate the developing CNS [22, 23]. Microglia cell
populations are maintained and proliferate via self-renewal,
without recruitment of peripheral precursors from the
blood [24, 25].
Microglia were considered quiescent in the absence of
CNS damage, reflected in classification of cells with
long, ramified processes and small cell bodies as ‘resting’
microglia. In fact, microglia are highly dynamic with mo-
tile processes which extend and retract rapidly over a
period of seconds to minutes within non-overlapping
microdomains [7, 26, 27], providing constant environ-
mental surveillance in addition to injury response. Con-
sequently, CNS insult induces an immediate tropic
response towards the injury site mediated by extracellu-
lar ATP signaling via P2Y12 [26, 28]. The physiological
functions of microglia have now been shown to be far
more diverse, with fundamental roles in ensuring healthy
CNS functioning through phagocytic clearing of cellular
debris, responding to and modulating neuronal activity,
influencing synaptic pruning and maturation as well as
modulating synaptic plasticity [29–34]. Misregulation of
this normal dynamic functioning of microglia can con-
tribute to pathology associated with disease or injury,
and a prime example of this is the role of microglia in
nerve injury-induced chronic pain.
Spinal microglial reactivity after injury to
peripheral nerves
PNI produces a stereotypical response in spinal microglia
characterized by proliferation around central terminals and
cell bodies of the peripherally damaged sensory and motor
nerves respectively. The proliferative response is dependent
on resident spinal microglia, as there is little, if any, infiltra-
tion of bone marrow-derived cells [35] or monocytes [36]
after peripheral nerve injury. Although a striking and con-
sistent response after PNI, it is unknown whether microglial
proliferation in the dorsal horn is necessary for PNI-pain
hypersensitivity. But, it is clear that the proliferation of
microglia per se is not sufficient for that development of
PNI-induced pain hypersensitivity [36–39]. Thus, a prolifer-
ative microglial response should not be considered as a
proxy measure of pain [40]. Proliferation is accompanied by
retraction of ramified processes and adoption of an
amoeboid morphology and changes in expression of cell-
surface proteins [41]. PNI activates de novo colony-
stimulating factor 1 (CSF1) production in injured sensory
neurons, which is transported to the spinal cord and binds
to CSF1 receptors on microglia [25]. CSF1 activity simul-
taneously engages a membrane adaptor protein DAP12-
independent pathway responsible for microglial
proliferation and a DAP12-dependent pathway mediating
upregulation of microglial genes associated with pain
hypersensitivity, including Irf8 and Irf5. [25, 37, 42]. In-
creases in IRF8 expression after PNI activates IRF5 which
binds specifically to the promotor of P2rx4, leading to an
upregulation of P2X4 receptor (P2X4R) expression on
microglia [37, 42] (see Fig. 1).
Similar to signals in ascending pathways such as CSF1,
descending serotonergic signalling has also been impli-
cated in inducing spinal microglia reactivity [43] and fa-
cilitation of pain hypersensitivity [43, 44]. Alleviation of
pain hypersensitivity occurs after inhibition of spinal 5-
HT3 receptors in nerve-injured animals [43]. Further-
more, intrathecal application of a 5-HT3 agonist results
in glial reactivity and development of hypersensitivity in
rats [43]. Additionally, spinal microgliosis due to periph-
eral inflammation can be attenuated by depletion of the
5-HT system [43].
Microglia signalling in the spinal cord
Upregulation and activation of microglial P2X4R expres-
sion in the spinal dorsal horn has been found to be neces-
sary for development of PNI-induced pain hypersensitivity
[5, 7]: pharmacological suppression of spinal P2X4Rs at-
tenuates PNI-induced pain hypersensitivity [5], and P2X4-
deficient mice (P2X4
−/−) show a lack of hypersensitivity
after PNI [38]. In addition, adoptive transfer of ATP-
stimulated microglia into naïve rats produces hypersensi-
tivity [5] and sensitization of lamina I dorsal horn neurons
[45] similar to that seen in nerve injured rodents. Activa-
tion of microglial P2X4Rs, by ATP released from dorsal
horn neurons [46], evokes an influx of extracellular cal-
cium, phosphorylating p38 MAP kinase and results in re-
lease of brain derived neurotrophic factor (BDNF) [6, 47].
Microglial BDNF secretion is impaired in P2X4-deficient
mice [38]. Furthermore, deletion of microglial BDNF
(CX3CR1
CreER x loxP-Bdnf) both prevents and reverses
PNI-induced hypersensitivity in mice [8].
Secreted BDNF stimulates neuronal TrkB receptors in
the dorsal horn initiating downregulation of potassium
chloride co-transporter KCC2 and a consequent shift in
the transmembrane anion gradient [6, 48]. KCC2 main-
tains neuronal chloride extrusion, ensuring low intracel-
lular chloride concentrations [49]. γ-aminobutyric acid
type A (GABAA) receptor functioning depends on the
chloride gradient; thus, increased intracellular chloride
due to KCC2 downregulation impairs GABA-mediated
inhibitory synaptic transmission [50]. Pharmacological
blockade or antisense knockdown of KCC2 produces
hypersensitivity in naïve rodents [48]. Pharmacological
activation of KCC2 reduces intracellular chloride con-
centration and alleviates hypersensitivity in nerve-injury
models [51]. Reduced chloride extrusion capacity also
promotes an efflux of HCO3
− anions through GABAA
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channels which further enhances GABA-mediated disin-
hibition [52]. Carbonic anhydrase (CA) is a family of en-
zymes which catalyzes the synthesis of HCO3
− [53].
Inhibition of CA alleviates nerve-injury induced hyper-
sensitivity, likely by decreasing the depolarizing efflux of
HCO3
− [52]. The consequence of disinhibition is
therefore a net increase in excitability of lamina 1 neu-
rons, which transforms spinal output and produces the
hallmark symptoms of neuropathic pain in rodents [45,
48].
In addition to disinhibition, facilitated excitation pro-
duced by Src kinase-mediated enhancement of NMDAR
Fig. 1 Schematic showing the cellular and molecular pathway involved in neuropathic pain following peripheral nerve injury (top). The presence
and/or relevance of the pathway in males and females is shown where elements of the pathway lie on the blue (male) and pink (female) lines. A
solid line indicates evidence exists for involvement in that sex; a broken line indicates either absence of evidence or yet to be tested. Pathway
components in red show known involvement in spinal changes leading to reduced inhibition, increased excitation and resultant increase in pain
hypersensitivity. See text for further details
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currents [54] contributes to hyperexcitability of lamina 1
projection neurons and associated pain hypersensitivity
[55]. Src is a non-receptor protein tyrosine kinase with
diverse physiological functions [56]. Src binding to the
NMDAR complex via NADH dehydrogenase subunit 2
(ND2) increases NMDAR activity [57]. Enhancement of
NMDAR function amplifies glutamatergic synaptic
transmission, increasing the output of lamina 1 neurons.
Uncoupling of Src kinase from the NMDAR complex
blocks Src-mediated NMDAR activity enhancement [57].
Furthermore, intrathecal application of a peptide that
disrupts Src binding alleviates nerve-injury induced pain
hypersensitivity [55]. The factors mediating Src-ND2
binding after PNI are not fully understood. Microglial
BDNF may be fundamental to this process as intrathecal
BDNF in naïve rodents potentiates NMDARs in a Src
family kinase-dependent manner [58] and potentiation
of NMDAR currents due to nerve injury is dependent
on BDNF signalling [59]. Cytokines can also enhance
NMDAR function through Src activation [60]. Further-
more, chloride-mediated disinhibition is required for po-
tentiation of NMDAR activity after nerve injury [59].
Thus, multiple signalling molecules may contribute to
NMDAR-enhancement after PNI.
Sexually dimorphic role of microglia in pain
The microglia-neuronal signalling pathway was estab-
lished through experiments using almost exclusively male
rodents; thus, its role in pain processing was not estab-
lished in females. Recent experiments using mice of both
sexes have shown that microglia are not involved in medi-
ating pain hypersensitivity in females with PNI, suggesting
the existence of sexually dimorphic pain processing [8].
The first indication of sexually dimorphic pain processing
was evidence showing that spinal TLR4s, which are
expressed specifically on microglia in the CNS, contribute
to PNI-induced pain hypersensitivity in male but not female
mice [61]. TLR4 is a member of the Toll-like receptor fam-
ily involved in response to pathogens such as bacterial lipo-
polysaccharide and consequent activation of the innate
immune system [62]. The sexually dimorphic role of TLR4
prompted broader investigation into the relevance of
microglia to neuropathic pain in female mice. Damage to a
peripheral nerve produces spinal microglial reactivity in fe-
male mice comparable to that of males [8, 63]. However,
application of intrathecal minocycline, propentofylline or
fluorocitrate, which may inhibit processes in glial cells, or
specific microglial lesioning (via intrathecal injection of
saporin toxin conjugated to the MAC-1 receptor) in mice
alleviates nerve injury-induced pain hypersensitivity in
males only and are entirely ineffective in females, suggest-
ing that microglia are not necessary for pain hypersensitiv-
ity in female mice [8]. Inhibition of spinal P2X4Rs
attenuates pain hypersensitivity in male but not female
mice, confirming that microglia neuronal signalling does
not contribute to pain processing in female mice [8]. p38
MAP kinase inhibition in the spinal cord is also ineffective
in attenuating hypersensitivity in female mice [8]. While
male microglial BDNF knockout mice (CX3CR1
CreER x
loxP-Bdnf) display significant impairments in development
and maintenance of PNI-induced hypersensitivity, pain pro-
cessing is unaffected in female knockout mice [8]. Further-
more, pharmacological inhibition of spinal BDNF reverses
hypersensitivity in males only, ruling out the possibility that
non-microglia derived BDNF contribute to female pain pro-
cessing [8]. Assessment of genes relevant to the microglia
neuronal signalling pathway demonstrated that upregula-
tion of P2rx4 is exclusive to male mice, indicating that the
P2X4R-dependent signalling pathway is not being engaged
in female mice, which may be the key to the sex depend-
ency of microglia in pain [8]. IRF8-IRF5 signalling lies up-
stream of P2X4R transcriptional upregulation [37, 42];
therefore, a sex difference in P2rx4 levels after nerve injury
may result from differential IRF8-IRF5 expression. How-
ever, PNI upregulates Irf8 and Irf5 expression equally in
both sexes, which could account for the microglial prolifer-
ation observed in females [8]. Thus, the inference is that
IRF5 mediated transcription of P2rx4 is likely not occurring
in females, which may be the key to the sex-dependency of
microglia in pain.
Sexual dimorphism of the microglia-neuron signalling
pathway has been confirmed elsewhere [64]. Inhibition of
spinal p38 MAP kinase alleviates nerve injury-induced
pain hypersensitivity in male but not female mice as well
as rats, consistent with the more substantial p38 phos-
phorylation levels after injury in males [64]. Furthermore,
spontaneous excitatory postsynaptic currents (EPSCs) are
depressed only in male lamina IIo neurons during p38
MAP kinase blockade [64]. This sex difference appears to
be spinally restricted as p38 MAP kinase inhibition
through intraperitoneal and perineural application routes
produces robust reversal in either sex [64]. The specificity
of this sex difference is consistent with the sexually di-
morphic role of spinal but not peripheral TLR4 in pain
[61]. However, recent evidence has shown that spinal
microglia are involved in mediating bone cancer pain in
female rats [65], which suggests that sex differences in
pain processing may not be consistent across injury
models. The contribution of descending serotonergic cir-
cuitry to neuropathic pain in females has yet to be investi-
gated, as previous work in investigating 5-HT3 was
conducted using male rodents only [43, 44].
Despite the absence of a role for microglia in mediating
neuropathic pain in females, there seems to be mechanis-
tic convergence at the neuronal level as antagonising
NMDAR activity alleviates pain hypersensitivity in both
sexes [8]. This suggests that despite a sex difference in up-
stream signalling, similar neuronal changes occur after
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nerve injury, i.e. potentiation of synaptic NMDAR activity.
Targeting convergent mechanisms between females and
males is an alternative strategy to development of sex-
specific therapies. It is still unknown whether the role for
NMDARs in female pain processing is Src kinase
dependent. Given the congruency in NMDAR involve-
ment between females and males, it is possible that disin-
hibition due to KCC2 downregulation also contributes to
pain behavior in both sexes. Investigation of whether im-
paired chloride extrusion mediates pain in females is crit-
ical given the interest in targeting KCC2 to treat
neuropathic pain [51]. Orally administered drugs which
rescue plasma membrane expression of KCC2 produce
strong analgesia in rodent models of PNI without loss of
motor function [51]. Such chloride extrusion enhancers
remain to be tested in females. If KCC2-dependent disin-
hibition is consistent between the sexes, this would indi-
cate that the sex difference in neuropathic pain processing
is restricted to immune system functioning.
The underlying cause of the sexual dimorphism in pain
processing remains unidentified; however, sex hormones
represent a strong candidate [66]. Engagement of the
microglial-dependent pathway appears to be contingent
on the presence of high testosterone levels, regardless of
sex [8]. Sex steroids have profound influences on immune
functioning and may be responsible for many sex differ-
ences in pain, see Rosen et al., 2017 for a in-depth review
of this topic [66]. Hormones also have been shown to
regulate gene transcription [67, 68]. Thus, future investi-
gation is required to determine whether sex steroids
underlie the differential upregulation of P2rx4 between
males in females after nerve injury.
Critical role for adaptive immune cells in females
That pain hypersensitivity in female mice is independent
of microglia, which are innate immune cells, led to con-
sidering the possibility that cells of the adaptive immune
system may be necessary in females [8]. It has been pre-
viously reported that male mice lacking adaptive
immune cells develop less hypersensitivity after nerve in-
jury [69, 70]. In contrast, it was found that nerve-injured
adaptive immune cell knockout mice (B6.129S7-Rag1tm1-
Mom/J and NU/J) display equivalent hypersensitivity to
their wildtype counterparts, regardless of sex. However,
interrogation of pain signalling mechanisms in these
mice revealed that females lacking adaptive immune
cells employ a microglia-dependent pathway in the me-
diation of pain hypersensitivity. Immune system recon-
stitution of female Rag1 knockouts with spleenocytes
causes a ‘switch’ to a microglia-independent pathway.
Therefore, it is hypothesized that the presence of adap-
tive immune cells, likely T cells, is necessary to drive the
non-microglia pathway (Fig. 1). T cells migrate into the
spinal cord after nerve injury and have been implicated
as key regulators of hypersensitivity [69–71].
T cells of mouse and human lineage display a
testosterone-dependent sex difference in expression of per-
oxisome proliferator activated receptors (PPARs), transcrip-
tion factors integral in cytokine regulation [72]. Expression
of PPARα is augmented by testosterone, which boosts se-
cretion of interleukin-17A [72]. Conversely, testosterone
decreases expression of PPARγ, which suppresses produc-
tion of interferon-γ [72]. Infiltrating cells into the spinal
cord after nerve injury appear to be primarily T helper type
1 (Th1) lymphocytes [73]. As interferon-γ is the prototyp-
ical Th1 cytokine, infiltrated T cells in nerve-injured male
mice may secrete fewer pro-inflammatory mediators rela-
tive to females. Consistent with sexually dimorphic PPAR
expression, intrathecal application of the PPARα agonist,
fenofibrate, attenuates nerve injury-induced hypersensitivity
in male mice only, a drug effect abolished by castration [8].
Furthermore, intrathecal administration of the PPARγ
agonist, pioglitazone, reverses hypersensitivity after nerve
injury in females, but not males [8]. Pioglitazone-mediated
analgesia in females is attenuated by treatment with testos-
terone propionate [8]. In addition to sex differences in T
cell phenotype, female mice also have higher peripheral and
central T cell counts than male mice [8]. Combined, differ-
ential T cell numbers and cytokine secretion could lead to
sexually dimorphic involvement of T cells in pain process-
ing. A T cell driven mechanism could also directly supress
the microglia-dependent pathway through inhibition of
P2rx4 transcription.
Hypersensitivity resulting from a sciatic nerve injection
of myelin basic protein (MBP) in female rats is also medi-
ated by T cells [74]. MBP has also been implicated in the
development of PNI-induced hypersensitivity in females
[75]. Thus, MBP-mediated activation of T cells may repre-
sent a component of the microglia-independent pathway.
T cells could release pro-inflammatory cytokines to pro-
duce neuronal changes, such as enhancement in NMDAR
functioning, which result in hyperexcitability of spinal
nociceptive circuitry. B cells may also represent a critical
mediator of the microglial-independent pathway. How-
ever, nerve injury does not induce spinal infiltration of B
cells in male mice [70] and little evidence has implicated B
cells in pain processing. The exact role for adaptive im-
mune cells and MBP in mediating pain in females requires
further investigation.
Relevance to clinical pain in humans
The role of microglia in chronic pain in humans of either
sex remains unclear. Significant differences exist in im-
mune system functioning between rodents and humans,
which poses issues for translation of preclinical findings to
humans [76, 77]. Post-mortem analysis of spinal cord tis-
sue has shown significant microglial and astrocytic
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activation in a female patient with longstanding complex
regional pain syndrome [78]. In post-mortem tissue of
male patients with HIV-associated neuropathic pain,
astrocytic but not microglial markers are upregulated in
the spinal dorsal horn [79]. In-vivo imaging of patients of
both sexes with chronic low back pain shows evidence of
glial activation in the brain [80]. Female and male patients
with peripheral nerve injury display activation of glial cells
in the thalamus [81]. Thus, there is evidence that glial
cells, including microglia, are activated in certain chronic
pain conditions. This glial reactivity is observed in patients
of both sexes [78–81], which is consistent with the pre-
clinical data [8]. Given the dissociation between microglial
proliferation and pain hypersensitivity, it cannot be con-
cluded that microglia in humans of either sex are involved
chronic pain per se [40].
The preclinical literature on microglia and pain has
sparked significant interest in targeting microglia in order
to treat chronic pain in humans. However, a clinical trial of
propentofylline, a glial modulating drug, failed to show effi-
cacy in treating pain in patients with post-herpetic neuralgia
[82]. It is possible that the dosing schedule of propentofyl-
line may not have been sufficient to achieve adequate spinal
glial inhibition. Additionally, post-herpetic neuralgia is not
strictly a nerve lesion, which has been the primary preclin-
ical model used to establish microglial involvement in pain
processing. Alternatively, the clinical trial may indicate a
lack of microglial involvement in neuropathic pain in
humans. Whether the efficacy of propentofylline in treating
neuropathic pain differs between women and men was not
reported. Thus, a possible sexually dimorphic role of micro-
glia in pain in humans cannot be ruled out.
Conclusions
Microglia have become a focus in the preclinical pain re-
search field. There is clear evidence in rodent models of
neuropathic pain that microglia are critical in mediating
pain behavior associated with nerve injury. However, the
evidence implicating microglia in pain comes almost exclu-
sively from experiments using male rodents. Recent re-
search has put into question our understanding of the role
of microglia in pain processing. While microglia adopt a re-
active phenotype following nerve injury in mice of both
sexes, these cells are not involved in mediating neuropathic
pain behavior in females. The cross-species generalizability
of this sexual dimorphism remains to be fully explored, but
preliminary evidence supports the existence of sex differ-
ences in pain signalling in rats with nerve injury. Sexually
dimorphic pain processing denotes the importance of in-
cluding animals of both sexes in preclinical research. The
translational potential of preclinical pain research may be
greatly improved with equal representation of male and fe-
male subjects and may lead to development of precision
medicine for chronic pain patients.
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